Related Experiment Video

Updated: Feb 25, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.8K

Pharmacogenomic considerations in the treatment of muscle-invasive bladder cancer

Tahlita Cm Zuiverloon1,2, Dan Theodorescu2

  • 1Department of Urology, Erasmus Medical Center, 3015 CE Rotterdam, The Netherlands.

Pharmacogenomics
|July 27, 2017
PubMed

Insights

Genomic alterations in bladder cancer impact chemotherapy effectiveness. Understanding chemoresistance mechanisms can improve patient selection and outcomes for muscle-invasive bladder cancer.

Area of Science:

  • Oncology
  • Genomics
  • Pharmacology

Background:

  • Next-generation sequencing advances have enhanced understanding of bladder cancer genomic alterations.
  • Cisplatin-based chemotherapy is a key treatment but faces significant chemoresistance challenges.
  • Mechanisms underlying treatment resistance in bladder cancer remain incompletely understood.

Purpose of the Study:

  • To review the mechanisms of chemoresistance in bladder cancer.
  • To summarize current knowledge on how genomic alterations influence treatment outcomes.
  • To provide insights for improved patient selection and therapeutic strategies.

Main Methods:

  • Literature review of recent advances in bladder cancer genomics.
  • Analysis of studies investigating chemoresistance mechanisms.
  • Synthesis of data linking genomic landscape to therapy response.

Main Results:

  • Genomic alterations play a crucial role in bladder cancer chemoresistance.
  • Elucidating resistance pathways can guide personalized treatment approaches.
  • Understanding these mechanisms is vital for improving patient outcomes.

Conclusions:

  • Targeting chemoresistance mechanisms is essential for effective bladder cancer treatment.
  • Genomic profiling can aid in selecting patients who will benefit from cisplatin-based chemotherapy.
  • Further research into the genomic landscape will optimize therapeutic strategies and reduce toxicity.
Keywords:
biomarkerbladder cancerpharmacogenomicstargeted therapy

More Related Videos

An Orthotopic Bladder Cancer Model for Gene Delivery Studies07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

13.2K
Culture of Bladder Cancer Organoids as Precision Medicine Tools08:39

Culture of Bladder Cancer Organoids as Precision Medicine Tools

Published on: December 28, 2021

5.5K

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
51
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
57
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
49
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
70
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
36
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
67